GRCE

Grace Therapeutics Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth↑ 8/10
  • Value↑ 5/10
Grace Therapeutics sales and earnings growth
GRCE Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 73.28%
  • FCF Y/Y↑ 27.96%
Grace Therapeutics gross and profit margin trends
GRCE Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↑ -1363.66%
Grace Therapeutics net debt vs free cash flow
GRCE Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Grace Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks